Corey Thompson, MD
Psychiatry · Mason City, IANPI 1932526217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,184 and has fallen 88.1% since, to $141 in 2023.
Across 155 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$494
- Lundbeck LLC$361
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$326
- Sunovion Pharmaceuticals Inc.$259
- Johnson & Johnson$252
- Otsuka America Pharmaceutical, Inc.$214
- plus $399 from 9 others
What the payments were for
- Food & beverage$2,305100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $494 |
| Lundbeck LLC | 26 | $361 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $326 |
| Sunovion Pharmaceuticals Inc. | 15 | $259 |
| Johnson & Johnson | 17 | $252 |
| Otsuka America Pharmaceutical, Inc. | 12 | $214 |
| Alkermes, Inc. | 7 | $127 |
| Neurocrine Biosciences, Inc. | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Indivior Inc. | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,305 in reported general payments places this provider in the 85th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 47 | $71,778 |
| Invega SustennaPaliperidone Palmitate | 16 | $55,844 |
| RexultiBrexpiprazole | 27 | $28,647 |
| CaplytaLumateperone Tosylate | 22 | $21,550 |
| TrintellixVortioxetine Hydrobromide | 18 | $12,392 |
| Vilazodone Hcl | 36 | $1,935 |
| Clozapine | 28 | $1,346 |
| Aripiprazole | 37 | $1,323 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $1,105 |
| Bupropion XlBupropion Hcl | 50 | $1,072 |
| Quetiapine Fumarate | 106 | $1,063 |
| Hydroxyzine Hcl | 49 | $952 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 100 | $910 |
| Olanzapine | 37 | $787 |
| Lamotrigine | 78 | $774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $494 | $71,77847 claims |
| Johnson & JohnsonInvega Sustenna | $252 | $55,84416 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $214 | $28,64727 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $326 | $21,55022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Mason City
- Mark LassiseMason City$8K
- Rogerio RamosMason City$6K
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Randall KavalierWest Des Moines$15K
- Dwight SchroederCedar Rapids$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.